Compugen Shares Up 12.0% Since SmarTrend's Buy Recommendation (CGEN)
Comtex SmarTrend(R) - Mon Dec 22, 10:00AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on December 5th, 2014 at $7.77. In approximately 2 weeks, Compugen has returned 11.97% as of today's recent price of $8.70.
CGEN: 8.58 (-0.17)
Compugen (CGEN) Worth a Look: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Compugen Ltd. (CGEN) was a big mover last session, as the company saw its shares rise over 5% on the day.
CGEN: 8.58 (-0.17), AFFX: 9.80 (+0.05)
Compugen teams up with Johns Hopkins in cancer research
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 6:58AM CST
CGEN: 8.58 (-0.17)
Compugen Enters Immuno-Oncology Research Collaboration with Johns Hopkins University
Business Wire - Thu Dec 18, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced the initiation of a multi-year research collaboration with Johns Hopkins University, School of Medicine, under the direction of Prof. Drew Pardoll and Dr. Charles Drake. Prof. Pardoll and Dr. Drake, members of Compugen's Scientific Advisory Board, are pioneers in the field of immuno-oncology. The collaboration will focus on further evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. This evaluation will include the candidates' differentiation profile with respect to known checkpoints and their potential to serve either for monotherapy or in combination with other cancer treatments.
CGEN: 8.58 (-0.17)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Will Compugen (CGEN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:39AM CST
Will Compugen (CGEN) Continue to Surge Higher?
CGEN: 8.58 (-0.17)
Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:25AM CST
Compugen (CGEN) was a big mover last session, with shares rising nearly 9% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), CGEN: 8.58 (-0.17), AFFX: 9.80 (+0.05)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 340.89 (+5.13), GILD: 91.29 (+1.84), CGEN: 8.58 (-0.17), ASPX: 49.93 (-0.10), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01)
Compugen to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Wed Dec 03, 6:01AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Office of Compugen, will present a company overview at the Oppenheimer 25th Annual Healthcare Conference in New York on Wednesday, December 10 at 2:10 p.m. ET.
CGEN: 8.58 (-0.17)
Shares of CGEN Down 14.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 02, 5:08PM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 2 months, Compugen has returned 13.96% as of today's recent price of $6.75.
CGEN: 8.58 (-0.17)
Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints
Business Wire - Tue Dec 02, 6:07AM CST
--Successful initial experimental results reported for drug target candidate identified through new methodology
CGEN: 8.58 (-0.17)
Investors' Radars Failed to Catch Compugen (CGEN), Has Yours? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:54AM CST
Compugen has seen a negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
CGEN: 8.58 (-0.17)
Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen
Brian Coleman - at Seeking Alpha - Fri Nov 21, 11:21AM CST
PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26), CGEN: 8.58 (-0.17), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)
Compugen (CGEN) Worth Watching: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:51AM CST
Compugen Ltd. (CGEN) was a big mover last session, as its shares rose nearly 6% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), CGEN: 8.58 (-0.17), AMAG: 43.02 (+0.90)
17.1% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Wed Nov 19, 11:19AM CST
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on October 10th, 2014 at $7.85. In approximately 1 month, Compugen has returned 17.14% as of today's recent price of $6.50.
CGEN: 8.58 (-0.17)
Compugen (CGEN) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:45AM CST
Compugen (CGEN) Enters Oversold Territory
CGEN: 8.58 (-0.17)
Compugen Finance Wins Sustainability Award From Toronto Region Board of Trade
Marketwire Canada - Thu Nov 13, 10:20AM CST
Compugen Finance is proud to have won the Toronto Region Board of Trade's 2014 Business Excellence award for Sustainability. The Award was presented at the Business Excellence Awards Ceremony at Toronto Don Valley Hotel on 6 November 2014.
CGEN: 8.58 (-0.17)
Compugen to Present at Jefferies 2014 Global Healthcare Conference in London
Business Wire - Wed Nov 12, 6:02AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.
CGEN: 8.58 (-0.17)